Body Pharm CJC-1295 with DAC 2mg — Order Now on JCSG.org (UK)
Body Pharm CJC-1295 with DAC 2mg is available now on JCSG.org for UK researchers. This lyophilised research peptide features the Drug Affinity Complex that extends functional half-life to 6–8 days via covalent serum-albumin binding — making it the preferred long-acting GHRH analogue for multi-day laboratory assays. Use the buy box above to add it to your order and see today's live UK price.
Order Body Pharm CJC-1295 DAC 2mg →
Key Takeaways
- Available now on JCSG.org — check the buy box above for the current UK price.
- The Drug Affinity Complex extends half-life to 6–8 days by binding covalently to serum albumin, enabling multi-day exposure assays without re-dosing.
- Body Pharm is the labelled manufacturer; JCSG.org stocks the 2mg lyophilised vial with batch-specific purity documentation available on request.
- CJC-1295 DAC is legal to purchase as a research chemical in the UK but holds no MHRA marketing authorisation for human use.
- Reconstitute 2mg vials in 1 ml bacteriostatic water to yield a 2 mg/ml stock; store lyophilised powder at −20 °C and reconstituted solution at 2–8 °C.
What Is Body Pharm CJC-1295 with DAC?
Body Pharm CJC-1295 with DAC is a 2mg lyophilised research peptide supplied as a tetrasubstituted GHRH(1-29) analogue conjugated to a Drug Affinity Complex (DAC), intended for laboratory and in vitro research use. JCSG.org is your trusted UK source for this Body Pharm product — see the current price and add it to your cart using the buy box above.
The DAC moiety separates this product from CJC-1295 without DAC (commonly sold as Modified GRF 1-29), which lacks the maleimidopropionic acid (MPA) linker and retains a short, minutes-scale plasma half-life. With DAC attached, the peptide forms a covalent bond to cysteine-34 on serum albumin, extending the functional half-life into the multi-day range. Teichman et al. (2006) reported this extension because the albumin-peptide complex circulates longer than free peptide before renal clearance.
Vial format and why researchers choose JCSG.org
The 2mg lyophilised vial is the dominant UK research format for CJC-1295 DAC. JCSG.org stocks Body Pharm's 2mg presentation with the quality documentation serious researchers require. For broader category context, see our CJC-1295 peptide overview or browse the full UK peptides catalogue.
How the DAC Mechanism Extends Half-Life
The Drug Affinity Complex extends CJC-1295's functional half-life by tethering the peptide to circulating serum albumin via a covalent thioether bond. This converts a minutes-scale GHRH analogue into a multi-day depot.
The maleimidopropionic acid (MPA) linker on the lysine side chain of the tetrasubstituted GHRH(1-29) backbone reacts with the free thiol of cysteine-34 on human serum albumin through Michael addition. Cys34 is the only reduced, surface-exposed cysteine on albumin, so the conjugation is selective and effectively irreversible under physiological conditions. The bond persists across the peptide's circulating lifespan.
Once bound, albumin acts as a slow-release reservoir. The conjugated peptide is shielded from dipeptidyl peptidase-IV cleavage and renal clearance, so active GHRH analogue is liberated gradually as albumin recycles. This is the structural basis for the commonly cited 6–8 day half-life of the DAC form, derived from Teichman et al.'s 2006 JCEM phase-1 reporting of an apparent terminal half-life of approximately 5.8–8.1 days.
Half-life comparison at a glance
| Variant | Linker chemistry | Reported half-life | Primary source |
|---|---|---|---|
| CJC-1295 without DAC (Modified GRF 1-29) | None | ~30 minutes (minutes-scale) | Secondary pharmacokinetic literature |
| CJC-1295 with DAC | MPA linker → Cys34 albumin conjugate | ~6–8 days (5.8–8.1 d) | Teichman et al., JCEM 2006 |
Why this matters for in vitro GH pulsatility work
For laboratory models probing sustained GH-axis stimulation, the no-DAC variant requires repeated dosing within a single experimental window to maintain receptor occupancy. The DAC-conjugated form supports continuous exposure assays over multi-day timescales without re-dosing artefacts, because the albumin depot maintains steady-state peptide release.
The albumin-bound depot flattens peak-trough variation, which is useful when isolating the contribution of GHRH receptor desensitisation from pharmacokinetic noise. Sustained GHRH receptor activation drives prolonged IGF-1 elevation in in vivo models. This distinction matters when designing IGF-1 transcription assays because transient pulses produce different gene-expression kinetics than sustained exposure.
CJC-1295 DAC vs CJC-1295 Without DAC: Key Differences
The practical research difference is exposure duration. CJC-1295 DAC sustains GHRH receptor occupancy over multi-day windows via covalent albumin binding. The non-DAC form (Modified GRF 1-29) produces a minutes-scale pulse suited to acute stimulation assays, because the unbound peptide is rapidly cleared by renal filtration and enzymatic degradation. Both variants are available on JCSG.org — see the CJC-1295 peptide overview to compare.
| Parameter | CJC-1295 with DAC | CJC-1295 without DAC (Modified GRF 1-29) |
|---|---|---|
| Albumin binding | Yes — covalent Cys34 conjugation via maleimidopropionyl linker | No |
| Reported half-life | ~6–8 days (5.8–8.1 d) | ~30 minutes (secondary literature) |
| Re-dosing within experimental window | Not required for multi-day exposure | Required to maintain receptor occupancy |
| IGF-1 elevation profile | Sustained over days | Transient, hours-scale |
| Vial size available on JCSG.org | 2 mg lyophilised | 2 mg lyophilised |
| Molecular weight | ~3367.9–3647.3 Da depending on salt form | ~3358 Da (free peptide) |
When to select the DAC form
For in vitro models requiring continuous GHRH receptor exposure — chronic desensitisation studies, multi-day pituitary cell culture work, or extended IGF-1 transcription assays — the DAC conjugate is the appropriate tool. Albumin-bound depot kinetics flatten the peak-trough variation inherent to the non-DAC variant and remove re-dosing confounds.
Acute signalling work, including receptor binding kinetics, cAMP response curves, or single-pulse GH release assays, is better served by Modified GRF 1-29. Rapid clearance prevents carryover between treatment conditions and allows precise temporal control of stimulus timing.
Ready to order? Use the buy box above or go straight to your JCSG.org cart.
Why Order Body Pharm CJC-1295 DAC 2mg from JCSG.org?
JCSG.org is the UK's dedicated destination for Body Pharm research peptides. When you order CJC-1295 DAC 2mg here you get:
- Genuine Body Pharm product — sourced direct, not grey-market grey imports.
- Batch-specific purity documentation — HPLC/MS certificates at ≥98% purity available on request.
- Live UK pricing — see the real current price in the buy box above; no inflated markups.
- Fast UK dispatch — shipped from within the UK, minimising customs exposure on unlicensed-medicine import rules.
- Research-grade quality assurance — lyophilised, not pre-mixed, so your vials arrive stable and ready to reconstitute.
Add to Cart — Order on JCSG.org →
For reference, Body Pharm's own product range is published at bodypharm.co.uk — JCSG.org is your authorised UK retail source for their peptides.
Research Dosage Protocol Overview for CJC-1295 DAC (In Vitro)
Research protocols for CJC-1295 DAC are structured around its multi-day half-life. Animal-model dosing is typically reported as once or twice weekly. In vitro assays use micromolar to nanomolar concentrations adjusted to the cell line, because the extended half-life allows lower-frequency administration than acute-acting GHRH analogues. The 2 mg lyophilised vial available on JCSG.org is most commonly reconstituted in 1 ml of bacteriostatic water to yield a 2 mg/ml (2,000 µg/ml) stock, with final assay concentrations diluted from that stock.
For laboratory and in vitro research use only. Not for human consumption.
Reported parameters at a glance
| Parameter | Reported value | Source / status |
|---|---|---|
| Vial format | 2 mg lyophilised powder | Body Pharm / JCSG.org product specification |
| Reconstitution solvent | Bacteriostatic or sterile water | Standard research guidance |
| Typical reconstitution volume | ~1 ml per 2 mg vial (yields 2 mg/ml) | General research guidance |
| Animal-model frequency | Once or twice weekly | Grey-literature extrapolation from Teichman et al., 2006 |
| Lyophilised storage | −20 °C, desiccated | General supplier guidance |
| Reconstituted storage | 2–8 °C, use within ~4 weeks | General supplier guidance |
| Half-life basis for frequency | ~5.8–8.1 days terminal | Teichman et al., JCEM 2006 |
Why DAC protocols diverge from Modified GRF 1-29
The maleimidopropionyl linker that covalently binds Cys34 on serum albumin extends the circulating half-life into days rather than minutes. Research schedules using CJC-1295 DAC cannot be ported across from Modified GRF 1-29 designs, where sub-hourly exposure windows dominate because the unbound peptide clears rapidly.
Treat the DAC form as a sustained-exposure tool in pulsatility studies and the no-DAC analogue as an acute-stimulus reagent, because their kinetic profiles support different experimental questions. Both are stocked on JCSG.org — see the CJC-1295 peptide overview.
Evidence gap to flag in your method section
No 2024–2026 peer-reviewed in vitro or animal study using "CJC-1295 DAC" by name with explicit concentration and frequency was identifiable in the indexed record. Researchers citing dosing schedules in a methods section should anchor to the Teichman et al. 2006 JCEM pharmacokinetic data and declare any extrapolation. That transparency allows readers to assess the evidence base.
Common Research Stacks: CJC-1295 DAC Combinations
The two combinations dominating the 2026 UK research literature for CJC-1295 DAC stacks are CJC-1295 DAC with Ipamorelin and CJC-1295 DAC with HGH Fragment 176-191. All compounds referenced below are available for research purchase on JCSG.org.
CJC-1295 DAC with Ipamorelin
The rationale for pairing CJC-1295 DAC with Ipamorelin is mechanistic complementarity. CJC-1295 DAC is a long-acting GHRH(1-29) analogue that binds Cys34 on serum albumin via its maleimidopropionyl linker. Ipamorelin is a selective ghrelin-receptor GHRP that triggers an acute secretory pulse, activating a distinct signalling pathway.
Pairing a sustained-exposure GHRH analogue with a short-acting GHRP allows researchers to model both tonic and phasic GH secretion within a single experimental design. Order both peptides together on JCSG.org — check the full UK peptides catalogue for current availability and pricing.
CJC-1295 DAC with HGH Fragment 176-191
HGH Fragment 176-191 is a C-terminal HGH-derived sequence studied for lipolytic activity. The pairing with CJC-1295 DAC covers both sustained GH-axis stimulation and downstream metabolic endpoints, making it a useful dual-compound design for body-composition research contexts. Both peptides are available now on JCSG.org.
Related repair and GHRH peptides
For adjacent research compounds, see the CJC-1295 peptide overview and the broader categories in our full UK peptides catalogue, including Tesamorelin (GHRH analogue), BPC-157, and TB500 (tissue repair context). All products are framed for laboratory research use only.
UK Regulatory Status of CJC-1295 DAC in 2026
CJC-1295 DAC is legal to purchase in the UK as a research chemical for laboratory use, but it holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation as a medicinal product and is not approved for human administration. The peptide is not scheduled under the Misuse of Drugs Act 1971 and is not captured by the Psychoactive Substances Act 2016. The Act excludes medicinal products and peptides acting on non-CNS endocrine targets from its scope, because they fall outside the definition of psychoactive substances.
JCSG.org supplies CJC-1295 DAC labelled "research use only" in accordance with the Human Medicines Regulations 2012 framework, ensuring compliant procurement for UK laboratory buyers. Procurement officers should verify current MHRA 2026 guidance and confirm internal compliance protocols before purchase. This section is informational and does not constitute legal advice.
| Regulatory instrument | Applies to CJC-1295 DAC? | Practical effect |
|---|---|---|
| Misuse of Drugs Act 1971 | No | Not a controlled drug |
| Psychoactive Substances Act 2016 | No | Peptides outside scope |
| Human Medicines Regulations 2012 | Conditional | Applies if presented for human use |
| MHRA marketing authorisation | None held | No licensed medicinal product |
What to Check Before Buying CJC-1295 DAC in the UK
Six procurement criteria separate a defensible research purchase from a compliance risk: purity documentation, supplier jurisdiction, physical format, vial size, shipping conditions, and labelling. JCSG.org meets all six — here is how we benchmark against each criterion.
| Criterion | JCSG.org standard | Why it matters |
|---|---|---|
| HPLC/MS purity certificate | ≥98% batch-specific CoA available on request | Below 98% introduces uncharacterised impurities into assay data and compromises result reproducibility |
| Third-party purity testing | Body Pharm batch documentation available; independent confirmation on request | Independent confirmation beats vendor self-declaration because it removes financial incentive to overstate purity |
| Supplier location | UK-dispatched stock | Reduces Border Force exposure on unlicensed-medicines import rules |
| Format | Lyophilised peptide, not pre-mixed liquid | Dry peptide is stable at 2–8 °C for months. Reconstituted CJC-1295 DAC degrades faster because dissolved peptide is vulnerable to hydrolysis and microbial contamination |
| Vial size | 2 mg standard | Match to assay throughput to avoid freeze-thaw cycles that degrade reconstituted peptide |
| Labelling | Explicit "research use only" wording | Required for compliant position outside Human Medicines Regulations 2012 |
Ready to place your order? Use the buy box above or go directly to your JCSG.org cart. For a full purity benchmark across the category, see the CJC-1295 peptide overview and the wider UK peptides catalogue.
Red flags to reject when sourcing elsewhere
Pre-mixed liquid vials without stability data warrant rejection because reconstituted peptide degrades unpredictably. A missing CoA on request signals the supplier cannot or will not verify batch identity. Non-UK dispatch with no customs documentation creates regulatory exposure. No "research use only" statement on the product page suggests the supplier may not have implemented the legal positioning required to remain outside medicinal-product regulation. A vendor refusing to share an HPLC/MS purity certificate on a batch-specific basis is the single strongest reason to walk away — it indicates either poor quality control or deliberate opacity. JCSG.org provides all required documentation as standard.
Frequently Asked Questions
| Question | Short answer |
|---|---|
| Half-life of CJC-1295 with DAC | 6–8 days, derived from Teichman et al. 2006 |
| Difference vs Modified GRF 1-29 | DAC adds covalent albumin binding; no-DAC variant clears in ~30 minutes |
| Current UK price | See the live buy box above on JCSG.org |
| Legal status in UK | Sold as research chemical; no MHRA marketing authorisation |
| Reconstitution volume, 2mg vial | ~1 ml bacteriostatic water for 2 mg/ml stock |
| Body Pharm purity documentation | Batch-specific HPLC/MS CoA available on request from JCSG.org |
What is the half-life of CJC-1295 with DAC?
CJC-1295 with DAC has a reported terminal half-life of approximately 6–8 days in healthy adults, traced to the Teichman et al. 2006 JCEM phase-1 trial that recorded 5.8–8.1 days depending on dose. The extension comes from covalent attachment to serum albumin via a maleimidopropionyl linker reacting with Cys34, which shields the peptide from enzymatic degradation and renal clearance.
How does CJC-1295 DAC differ from Modified GRF 1-29?
Modified GRF 1-29 (CJC-1295 without DAC) is the same tetrasubstituted GHRH(1-29) backbone but lacks the Drug Affinity Complex linker, giving it a minutes-scale half-life often quoted as roughly 30 minutes in secondary literature. The DAC variant produces sustained GH pulsatility flattening and downstream IGF-1 elevation across days rather than a single pulse, because the albumin depot maintains steady-state peptide release. Both variants are available on JCSG.org.
What is the current UK price for CJC-1295 DAC 2mg?
The live current price is shown in the buy box at the top of this page on JCSG.org. We keep pricing up to date and competitive — no need to shop around. See the CJC-1295 peptide overview for category-level context.
Can I legally buy CJC-1295 DAC in the UK?
CJC-1295 DAC has no MHRA-authorised medicinal product in the UK and is supplied as a research-only peptide rather than a licensed prescription medicine. JCSG.org labels all products "research use only" to remain outside the Human Medicines Regulations 2012 framework. The peptide is not listed under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016.
What is the recommended reconstitution volume for a 2mg vial?
Reconstituting a 2mg vial in 1 ml of bacteriostatic water yields a 2 mg/ml (2,000 µg/ml) stock. UK research guidance confirms solubility in sterile or bacteriostatic water; leave the final working concentration to your assay requirements, as they vary by cell type and endpoint.
Is Body Pharm CJC-1295 DAC third-party tested?
Batch-specific HPLC/MS purity certificates are available on request from JCSG.org. Benchmark all documentation against the ≥98% HPLC purity standard maintained across our UK peptides catalogue. Contact our team if you require documentation before placing your order.
Order Body Pharm CJC-1295 DAC 2mg Now
JCSG.org is the fastest, most reliable way to get Body Pharm CJC-1295 DAC 2mg delivered to your UK laboratory. Use the buy box above to check today's live price and place your order, or go straight to your cart. Need to compare with other GHRH-axis research compounds? Browse the CJC-1295 peptide overview or the full UK peptides catalogue to find everything you need in one place.
Order Now on JCSG.org →
